[{"address1": "260 Sheridan Avenue", "address2": "Suite 400", "city": "Palo Alto", "state": "CA", "zip": "94306", "country": "United States", "phone": "650 800 6676", "website": "https://vincerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ahmed M. Hamdy M.D.", "age": 59, "title": "Co-Founder & Chairman", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 657537, "exercisedValue": 0, "unexercisedValue": 12075}, {"maxAge": 1, "name": "Dr. Raquel E. Izumi Ph.D.", "age": 55, "title": "Co-Founder, Acting CEO, Secretary & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 591540, "exercisedValue": 0, "unexercisedValue": 12075}, {"maxAge": 1, "name": "Mr. Tom C. Thomas J.D.", "age": 64, "title": "Founder, General Counsel & Chief Legal Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 444142, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Byrd M.D.", "title": "Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  Haas", "age": 59, "title": "Acting CFO, VP of Finance & Corporate Controller", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans-Georg  Lerchen Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gabriela  Jairala", "title": "Vice President of Investor Relations & Corporate Communications and Chief of Staff", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Quarford M.B.A.", "title": "Vice President of Quality Operations & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Merrick SPHR", "title": "Senior Director of People & Culture and Head of Human Resource", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Beatrix  Stelte-Ludwig Ph.D.", "title": "Executive Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.32, "open": 1.36, "dayLow": 1.31, "dayHigh": 1.41, "regularMarketPreviousClose": 1.32, "regularMarketOpen": 1.36, "regularMarketDayLow": 1.31, "regularMarketDayHigh": 1.41, "forwardPE": -2.0895522, "volume": 93990, "regularMarketVolume": 93990, "averageVolume": 742423, "averageVolume10days": 2157239, "averageDailyVolume10Day": 2157239, "bid": 1.31, "ask": 1.45, "bidSize": 400, "askSize": 400, "marketCap": 3135412, "fiftyTwoWeekLow": 1.31, "fiftyTwoWeekHigh": 187.44, "fiftyDayAverage": 3.6644, "twoHundredDayAverage": 10.3606, "currency": "USD", "enterpriseValue": 38531264, "floatShares": 26769893, "sharesOutstanding": 2239580, "sharesShort": 55653, "sharesShortPriorMonth": 20979, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.0249, "heldPercentInsiders": 0.115930006, "heldPercentInstitutions": 0.18638, "shortRatio": 0.05, "shortPercentOfFloat": 0.0274, "impliedSharesOutstanding": 36467100, "bookValue": 0.425, "priceToBook": 3.2941175, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -26322000, "trailingEps": -18.24, "forwardEps": -0.67, "lastSplitFactor": "1:20", "lastSplitDate": 1738022400, "enterpriseToEbitda": -1.406, "52WeekChange": -0.9576923, "SandP52WeekChange": 0.21027291, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VINC", "underlyingSymbol": "VINC", "shortName": "Vincerx Pharma, Inc.", "longName": "Vincerx Pharma, Inc.", "firstTradeDateEpochUtc": 1590586200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "46789548-9ff1-3829-9a39-73e43f85b2b7", "messageBoardId": "finmb_690173412", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.4, "targetHighPrice": 200.0, "targetLowPrice": 40.0, "targetMeanPrice": 120.0, "targetMedianPrice": 120.0, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 10086000, "totalCashPerShare": 0.301, "ebitda": -27411000, "totalDebt": 1639000, "quickRatio": 2.055, "currentRatio": 2.166, "debtToEquity": 17.995, "returnOnAssets": -0.83273005, "returnOnEquity": -2.11856, "freeCashflow": -19563750, "operatingCashflow": -27965000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]